Intravitreal ranibizumab injection combined with panretinal photocoagulation for the treatment of neovascular glaucoma

中华眼外伤职业眼病杂志 Pub Date : 2019-11-25 DOI:10.3760/CMA.J.ISSN.2095-1477.2019.11.011

Yongcheng Hu, Zhike Zhang, Ping Zhang, Xudong Zhang

{"title":"Intravitreal ranibizumab injection combined with panretinal photocoagulation for the treatment of neovascular glaucoma","authors":"Yongcheng Hu, Zhike Zhang, Ping Zhang, Xudong Zhang","doi":"10.3760/CMA.J.ISSN.2095-1477.2019.11.011","DOIUrl":null,"url":null,"abstract":"Objective \nTo observe the efficacy of intravitreal ranibizumab injection with panretinal photocoagulation for the treatment of neovascular glaucoma. \n \n \nMethods \nTotal of 20 eyes of 20 cases with neovascular glaucoma in Bayannur Federation of Disabled People’s Eye Hospital from Jan. 2015 to Feb. 2018 were analyzed retrospectively. All cases were treated with intravitreal ranibizumb injection(0.5 mg/0.05 ml)and panretinal photocoagulation at 1 week after injection. \n \n \nResults \nThe IOP was(19.45±8.54)mmHg(1mmHg=0.133 kPa)at 3 months after treatment, which was significantly lower than that before treatment(41.80±9.84)mmHg(P=0.000). The visual acuity was improved significantly (P=0.000). The new vessels of iris and anterior chamber angle basically disappeared. There was no serious complication or adverse reactions in all patients. \n \n \nConclusion \nIntravitreal ranibizunmb injection combined with panretinal photocoagulation for the treatment of neovascular glaucoma can significantly reduce the IOP and improve visual function of the patients without obvious adverse reactions. \n \n \nKey words: \nGlaucoma, neovascular; Ranibizumab; Injection, intravitreal; Photocoagulation, panretinal","PeriodicalId":10126,"journal":{"name":"中华眼外伤职业眼病杂志","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华眼外伤职业眼病杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.2095-1477.2019.11.011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective To observe the efficacy of intravitreal ranibizumab injection with panretinal photocoagulation for the treatment of neovascular glaucoma. Methods Total of 20 eyes of 20 cases with neovascular glaucoma in Bayannur Federation of Disabled People’s Eye Hospital from Jan. 2015 to Feb. 2018 were analyzed retrospectively. All cases were treated with intravitreal ranibizumb injection(0.5 mg/0.05 ml)and panretinal photocoagulation at 1 week after injection. Results The IOP was(19.45±8.54)mmHg(1mmHg=0.133 kPa)at 3 months after treatment, which was significantly lower than that before treatment(41.80±9.84)mmHg(P=0.000). The visual acuity was improved significantly (P=0.000). The new vessels of iris and anterior chamber angle basically disappeared. There was no serious complication or adverse reactions in all patients. Conclusion Intravitreal ranibizunmb injection combined with panretinal photocoagulation for the treatment of neovascular glaucoma can significantly reduce the IOP and improve visual function of the patients without obvious adverse reactions. Key words: Glaucoma, neovascular; Ranibizumab; Injection, intravitreal; Photocoagulation, panretinal

查看原文本刊更多论文

雷尼单抗玻璃体内注射联合全视网膜光凝治疗新生血管性青光眼

目的观察雷尼单抗玻璃体内注射联合全视网膜光凝治疗新生血管性青光眼的疗效。方法回顾性分析2015年1月至2018年2月巴彦淖尔残疾人联合会眼科医院收治的20例新生血管性青光眼患者的20只眼。所有病例均给予玻璃体内注射雷尼单(0.5 mg/0.05 ml)，注射后1周进行全视网膜光凝治疗。结果治疗后3个月IOP为(19.45±8.54)mmHg(1mmHg=0.133 kPa)，显著低于治疗前(41.80±9.84)mmHg(P=0.000)。视力明显改善(P=0.000)。虹膜及前房角新生血管基本消失。所有患者均无严重并发症和不良反应。结论玻璃体内注射雷尼珠单抗联合全视网膜光凝治疗新生血管性青光眼可显著降低患者IOP，改善视功能，无明显不良反应。关键词:青光眼;新生血管;之初;注入,intravitreal;凝固,全

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中华眼外伤职业眼病杂志

自引率

0.00%

发文量

8728

期刊介绍：